Disc Medicine, Inc.: bitopertin

With respect to the first factor, we agree that Trial 201, one adequate and well controlled trial, demonstrated an effect on its primary endpoint.

Confirmatory evidence was provided from a second, randomized, open-label rial, Trial 202, in which bitopertin 60 mg was superior to bitopertin 20 mg for the primary biomarker endpoint of percent change from baseline to Day 169 of whole blood metalree PPIX in adult and adolescent patients with EPP or XLP (p=0.018).